These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Structural basis of lenalidomide-induced CK1α degradation by the CRL4(CRBN) ubiquitin ligase. Petzold G; Fischer ES; Thomä NH Nature; 2016 Apr; 532(7597):127-30. PubMed ID: 26909574 [TBL] [Abstract][Full Text] [Related]
3. Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN.). Gandhi AK; Kang J; Havens CG; Conklin T; Ning Y; Wu L; Ito T; Ando H; Waldman MF; Thakurta A; Klippel A; Handa H; Daniel TO; Schafer PH; Chopra R Br J Haematol; 2014 Mar; 164(6):811-21. PubMed ID: 24328678 [TBL] [Abstract][Full Text] [Related]
4. A genome-scale CRISPR-Cas9 screening in myeloma cells identifies regulators of immunomodulatory drug sensitivity. Liu J; Song T; Zhou W; Xing L; Wang S; Ho M; Peng Z; Tai YT; Hideshima T; Anderson KC; Cang Y Leukemia; 2019 Jan; 33(1):171-180. PubMed ID: 30026574 [TBL] [Abstract][Full Text] [Related]
5. UBE2G1 governs the destruction of cereblon neomorphic substrates. Lu G; Weng S; Matyskiela M; Zheng X; Fang W; Wood S; Surka C; Mizukoshi R; Lu CC; Mendy D; Jang IS; Wang K; Marella M; Couto S; Cathers B; Carmichael J; Chamberlain P; Rolfe M Elife; 2018 Sep; 7():. PubMed ID: 30234487 [TBL] [Abstract][Full Text] [Related]
7. Treatment of Lymphoid and Myeloid Malignancies by Immunomodulatory Drugs. Fuchs O Cardiovasc Hematol Disord Drug Targets; 2019; 19(1):51-78. PubMed ID: 29788898 [TBL] [Abstract][Full Text] [Related]
8. Lys-63-specific deubiquitinase BRCC36 enhances the sensitivity of multiple myeloma cells to lenalidomide by inhibiting lysosomal degradation of cereblon. Wang B; Li M; Cao D; Sun Q; Yu W; Ma J; Ren H; Xu G; Zhou L Cell Mol Life Sci; 2024 Aug; 81(1):349. PubMed ID: 39136771 [TBL] [Abstract][Full Text] [Related]
9. Genome-wide CRISPR screens reveal genetic mediators of cereblon modulator toxicity in primary effusion lymphoma. Patil A; Manzano M; Gottwein E Blood Adv; 2019 Jul; 3(14):2105-2117. PubMed ID: 31300418 [TBL] [Abstract][Full Text] [Related]
10. pSILAC mass spectrometry reveals ZFP91 as IMiD-dependent substrate of the CRL4 An J; Ponthier CM; Sack R; Seebacher J; Stadler MB; Donovan KA; Fischer ES Nat Commun; 2017 May; 8():15398. PubMed ID: 28530236 [TBL] [Abstract][Full Text] [Related]
11. CK1α and IRF4 are essential and independent effectors of immunomodulatory drugs in primary effusion lymphoma. Patil A; Manzano M; Gottwein E Blood; 2018 Aug; 132(6):577-586. PubMed ID: 29954751 [TBL] [Abstract][Full Text] [Related]
13. A novel effect of thalidomide and its analogs: suppression of cereblon ubiquitination enhances ubiquitin ligase function. Liu Y; Huang X; He X; Zhou Y; Jiang X; Chen-Kiang S; Jaffrey SR; Xu G FASEB J; 2015 Dec; 29(12):4829-39. PubMed ID: 26231201 [TBL] [Abstract][Full Text] [Related]
14. Generation of a lenalidomide-sensitive syngeneic murine in vivo multiple myeloma model by expression of Crbn Röhner L; Ng YLD; Scheffold A; Lindner S; Köpff S; Brandl A; Beilhack A; Krönke J Exp Hematol; 2021 Jan; 93():61-69.e4. PubMed ID: 33186626 [TBL] [Abstract][Full Text] [Related]
15. Structure of the DDB1-CRBN E3 ubiquitin ligase in complex with thalidomide. Fischer ES; Böhm K; Lydeard JR; Yang H; Stadler MB; Cavadini S; Nagel J; Serluca F; Acker V; Lingaraju GM; Tichkule RB; Schebesta M; Forrester WC; Schirle M; Hassiepen U; Ottl J; Hild M; Beckwith RE; Harper JW; Jenkins JL; Thomä NH Nature; 2014 Aug; 512(7512):49-53. PubMed ID: 25043012 [TBL] [Abstract][Full Text] [Related]
16. Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDS. Krönke J; Fink EC; Hollenbach PW; MacBeth KJ; Hurst SN; Udeshi ND; Chamberlain PP; Mani DR; Man HW; Gandhi AK; Svinkina T; Schneider RK; McConkey M; Järås M; Griffiths E; Wetzler M; Bullinger L; Cathers BE; Carr SA; Chopra R; Ebert BL Nature; 2015 Jul; 523(7559):183-188. PubMed ID: 26131937 [TBL] [Abstract][Full Text] [Related]
17. [Molecular Mechanism of CRBN in the Activity of Lenalidomid eagainst Myeloma--Review]. Fan WJ; Fan ZQ; Yang MJ; Pan YZ; Bai H Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Aug; 26(4):1240-1243. PubMed ID: 30111438 [TBL] [Abstract][Full Text] [Related]
18. USP15 antagonizes CRL4 Nguyen TV Proc Natl Acad Sci U S A; 2021 Oct; 118(40):. PubMed ID: 34583995 [TBL] [Abstract][Full Text] [Related]
19. Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. Krönke J; Udeshi ND; Narla A; Grauman P; Hurst SN; McConkey M; Svinkina T; Heckl D; Comer E; Li X; Ciarlo C; Hartman E; Munshi N; Schenone M; Schreiber SL; Carr SA; Ebert BL Science; 2014 Jan; 343(6168):301-5. PubMed ID: 24292625 [TBL] [Abstract][Full Text] [Related]